Table 1.
Characteristics of patients with WM/LPL who underwent alloHCT reported to the CIBMTR
| Variable | All1 | MAC | RIC | p-value (MAC vs. RIC) |
|---|---|---|---|---|
| Number of Patients | 1442 | 67 | 67 | |
| Number of Centers | 84 | 39 | 45 | |
| Age at Transplant, years | 0.02 | |||
| Median Age | 53 (21-76) | 50 (21-66) | 53(34-76) | 0.008 |
| 21-49 | 55 (38) | 34 (51) | 18 (27) | |
| 50-59 | 63 (44) | 23 (34) | 35 (52) | |
| ≥ 60 | 26 (18) | 10 (15) | 14 (21) | |
| Gender: Male | 98 (68) | 44 (66) | 46(69) | 0.71 |
| Karnofsky score: <80% | 15 (10) | 6 (9) | 7 (10) | 0.74 |
| Region | ||||
| US | 109 (76) | 50 (75) | 50 (75) | 0.006 |
| Canada | 22 (15) | 15 (22) | 6 (9) | |
| Other2 | 13 (9) | 2 (2) | 11 (16) | |
| Graft Type | ||||
| Bone Marrow | 14 (10) | 12 (18) | 1 (1) | 0.001 |
| Peripheral Blood | 130 (90) | 55 (82) | 66 (99) | |
| Donor Type | 0.97 | |||
| HLA-identical sibling | 75 (52) | 36 (54) | 37(54) | |
| HLA-matched relative | 7 (5) | 3 (4) | 3 (4) | |
| HLA-matched non-relative | 57 (40) | 2 (3) | 2 (3) | |
| HLA-mismatched relative | 5 (3) | 26 (39) | 25 (37) | |
| Transplant-related | ||||
| Year of Transplant | 0.60 | |||
| 2001-2005 | 61 (42) | 27 (40) | 30 (45) | |
| 2006-2013 | 83 (58) | 40 (60) | 37 (55) | |
| Time from diagnosis to transplant | 0.66 | |||
| Median months (range) | 41 (<1-204) | 38 (<1-204) | 47 (<1-198) | 0.34 |
| <24 months | 52 (36) | 26 (39) | 21 (31) | |
| 24-60 months | 43 (30) | 20 (30) | 22 (33) | |
| >60 months | 49 (34) | 21 (31) | 24 (36) | |
| Disease Status prior to AlloHCT | 0.58 | |||
| Complete Response/CRu3 | 20 (14) | 11 (16) | 8 (12) | |
| Partial Response | 62 (43) | 28 (42) | 33 (49) | |
| Stable Disease | 7 (5) | 2 (3) | 5 (8) | |
| Progression/Relapse | 32 (22) | 16 (24) | 15 (22) | |
| Never Treated | 1 (11) | 1 (1) | 0 | |
| Unknown | 22 (15) | 9 (13) | 6 (9) | |
| Sensitivity to Chemotherapy | 0.56 | |||
| Sensitive | 82 (57) | 39 (58) | 41 (61) | |
| Resistant | 39 (27) | 18 (27) | 20 (30) | |
| Unknown | 23 (16) | 10 (15) | 6 (9) | |
| Prior AutoHCT | 18 (13) | 6 (9) | 6 (9) | 1 |
| Conditioning Regimen Intensity4 | ||||
| Myeloablative | 67 (47) | 67 (100) | 0 | |
| Reduced Intensity | 67 (47) | 0 | 67 (100) | |
| Unknown | 10 (7) | NA | NA | |
| Anti-thymocyte Globulin | 0.27 | |||
| No | 119 (81) | 57 (85) | 52 (78) | |
| Yes | 25 (19) | 10 (15) | 15 (22) | |
| GVHD prophylaxis | <0.001 | |||
| Cyclosporin-based | 37 (26) | 5 (8) | 28 (42) | |
| Methotrexate + Cyclosporin | 29 (20) | 20 (30) | 8 (12) | |
| Tacrolimus-based | 72 (50) | 37 (55) | 30 (45) | |
| Unknown | 6 (4) | 5 (8) | 1 (1) | |
| Medium Follow-up from Allo-HCT, months (range) | 70 (4-144) | 97 (4-143) | 35 (12-144) | 0.56 |
| Disease-related (research form only) | ||||
| Number of Patients | 36 | 18 | 18 | |
| Prior Lines of Chemotherapy | ||||
| 1-3 | 20 (56) | 8 (44) | 12 (67) | |
| >3 | 16 (44) | 10 (56) | 6 (33) | |
| Pre-alloHCT chemotherapy5 | ||||
| Cladribine/Fludurabine (+/− Chlorambucil) | 15 (42) | 8 (44) | 7 (39) | |
| Adriamycin-based | 14 (39) | 7 (39) | 7 (39) | |
| Bortezomib-based | 3 (8) | 1 (6) | 2 (11) | |
| Others3 | 4 (11) | 2 (11) | 2 (11) | |
| Pre-alloHCT Rituximab | 21 (58) | 12 (67) | 9 (50) | |
Data is displayed as the number of patient with the percent of patients shown in parentheses, unless otherwise noted.
Includes patients with unknown conditioning (n=10).
Central/South America (n=4), Australia/New Zealand (n=3), Asian (n=3), Mideast/Africa (3).
Unconfirmed complete response (CRu), not applicable (NA), not done (ND)
Conditioning regimens: Cytarabine (Cy) + Total body irradiation (TBI) (n=21), Fludarabine (Flu) + TBI (n=23), TBI + others (n=12), Busulfan (Bu) + Cy (n=10), Flu + Cy +/− TBI (n=19), Flu + Melphalan (Mel) (n=16), Flu + Bu (n=22), Mel (n=9), Carmustine, Etoposide, Cy, MEL (BEAM) (n=4), Total lymphoid irradiation + anti-thymocyte globulin (ATG) (n=5), Cy (n=1), ATG + Cy + Pentostatin (n=1), Bu + Rituximab + Pentostatin (n=1)
6. Other chemotherapies: Etoposide, Alemtuzumab, Imatinib, Procarabazine